Table S1. Treatment and Supportive Care for dose-adjusted R-EPOCH

|  |  |  |  |
| --- | --- | --- | --- |
| Drug | Dose | Route | Treatment Days |
| RituximabInfused agents\*EtoposideDoxorubicinVincristine | 375 mg/m250 mg/m2/day10 mg/m2/day0.4 mg/m2/day | IVPBCIVCIVCIV | 01,2,3,4 (96 hours)1,2,3,4 (96 hours)1,2,3,4 (96 hours) |
| Bolus agentsCyclophosphamide\*\* | Starting dose：375 mg/m2 if CD4+ cells = 50-200 cells/ul ormaximum dose of 750 mg/m2 if CD4+ cells >cells 200/ul | IVPB | 5 |
| Prednisone | 60 mg/m2/day | PO | 1,2,3,4,5 |
| FilgrastimOrPegfilgrastim | 5 µg/Kg6mg | SCSC once | 6 ANC >5000/µl (past nadir)6 |

CIV: intravenous continuous infusion, IVPB, intravenous piggyback, SC subcutaneous injection

\*Etoposide, doxorubicin, and vincristine could be admixed in the same solution. Etoposide, doxorubicin, and vincristine were never dose-adjusted for hematologic toxicity.

\*\*: Cyclophosphamide dose-adjustment (after cycle 1), if nadir ANC < 500/µl or platelets < 25 /µl, 187 mg/m2 below previous cycle.